Advertisement

Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Welcome and Introduction to Vi3C

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Advertisement

Advertisement




Mar
24
Today In Oncology
Awareness of Alcohol-Cancer Link Holds Steady Despite Omission in New US Dietary Guidelines
Myelofibrosis Treatment Landscape Is Poised for Change
AI Model Classifies Challenging Thymic Epithelial Tumors
Study Finds Inferior Survival Among Black Patients With AML, Independent of Cytogenetic Risk
Lisocabtagene Maraleucel in Relapsed or Refractory MZL
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo